InSite files with FDA for fluoroquinolone approval


Alameda, CA-InSite Vision Inc. has filed an investigational new drug application with the FDA for ISV-403, its treatment for ocular bacterial infections, under development with Bausch & Lomb.

Recent Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.